144 related articles for article (PubMed ID: 21457304)
1. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
Nuntnarumit P; Chongkongkiat P; Khositseth A
Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
Farombi-Oghuvbu I; Matthews T; Mayne PD; Guerin H; Corcoran JD
Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F257-60. PubMed ID: 18218660
[TBL] [Abstract][Full Text] [Related]
3. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants.
Nuntnarumit P; Khositseth A; Thanomsingh P
J Perinatol; 2009 Feb; 29(2):137-42. PubMed ID: 19020527
[TBL] [Abstract][Full Text] [Related]
4. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates.
Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T
J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347
[TBL] [Abstract][Full Text] [Related]
5. Elevated urinary NT-proBNP after pharmacological closure of patent ductus arteriosus in very low birth weight infants.
Celik IH; Erdeve O; Demırel G; Canpolat FE; Dilmen U
Early Hum Dev; 2013 Mar; 89(3):187-9. PubMed ID: 23084575
[TBL] [Abstract][Full Text] [Related]
6. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus.
Letzner J; Berger F; Schwabe S; Benzing J; Morgenthaler NG; Bucher HU; Bührer C; Arlettaz R; Wellmann S
Neonatology; 2012; 101(2):116-24. PubMed ID: 21952518
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes of brain-type natriuretic peptide in preterm neonates.
da Graca RL; Hassinger DC; Flynn PA; Sison CP; Nesin M; Auld PA
Pediatrics; 2006 Jun; 117(6):2183-9. PubMed ID: 16740863
[TBL] [Abstract][Full Text] [Related]
8. Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants.
Tosse V; Pillekamp F; Verde P; Hadzik B; Sabir H; Mayatepek E; Hoehn T
Neonatology; 2012; 101(4):260-6. PubMed ID: 22222353
[TBL] [Abstract][Full Text] [Related]
9. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants.
Ramakrishnan S; Heung YM; Round J; Morris TP; Collinson P; Williams AF
Acta Paediatr; 2009 Aug; 98(8):1254-9. PubMed ID: 19432837
[TBL] [Abstract][Full Text] [Related]
10. Urinary NT-proBNP and ductal closure in preterm infants.
Czernik C; Metze B; Müller C; Bührer C
J Perinatol; 2013 Mar; 33(3):212-7. PubMed ID: 22743407
[TBL] [Abstract][Full Text] [Related]
11. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
Attridge JT; Kaufman DA; Lim DS
Arch Dis Child Fetal Neonatal Ed; 2009 May; 94(3):F178-82. PubMed ID: 18981033
[TBL] [Abstract][Full Text] [Related]
12. N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool?
Hammerman C; Shchors I; Schimmel MS; Bromiker R; Kaplan M; Nir A
Pediatr Cardiol; 2010 Jan; 31(1):62-5. PubMed ID: 19859762
[TBL] [Abstract][Full Text] [Related]
13. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?
Lee JH; Shin JH; Park KH; Rhie YJ; Park MS; Choi BM
Neonatology; 2013; 103(2):118-22. PubMed ID: 23182972
[TBL] [Abstract][Full Text] [Related]
14. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
Supapannachart S; Limrungsikul A; Khowsathit P
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1252-8. PubMed ID: 12549803
[TBL] [Abstract][Full Text] [Related]
15. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.
Brooks JM; Travadi JN; Patole SK; Doherty DA; Simmer K
Arch Dis Child Fetal Neonatal Ed; 2005 May; 90(3):F235-9. PubMed ID: 15846015
[TBL] [Abstract][Full Text] [Related]
16. Management of patent ductus arteriosus in preterm infants.
Ekici F; Atasay B; Günlemez A; Naçar N; Tutar E; Atalay S; Eyileten Z; Uysalel A; Arsan S
Anadolu Kardiyol Derg; 2006 Mar; 6(1):28-33. PubMed ID: 16524797
[TBL] [Abstract][Full Text] [Related]
17. Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus.
Rheinlaender C; Helfenstein D; Pees C; Walch E; Czernik C; Obladen M; Koehne P
Early Hum Dev; 2010 Feb; 86(2):87-92. PubMed ID: 20153127
[TBL] [Abstract][Full Text] [Related]
18. Utility of N-terminal pro-brain natriuretic peptide for assessing hemodynamic significance of patent ductus arteriosus in dogs undergoing ductal repair.
Hariu CD; Saunders AB; Gordon SG; Norby B; Miller MW
J Vet Cardiol; 2013 Sep; 15(3):197-204. PubMed ID: 23933478
[TBL] [Abstract][Full Text] [Related]
19. Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus.
Bagnoli F; Rossetti A; Casucci M; Mori A
Minerva Pediatr; 2010 Jun; 62(3 Suppl 1):67-70. PubMed ID: 21089722
[TBL] [Abstract][Full Text] [Related]
20. Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus.
Weir FJ; Smith A; Littleton P; Carter N; Hamilton PA
Acta Paediatr; 1992 Sep; 81(9):672-5. PubMed ID: 1421905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
